Torin 1

Catalog No.S2827

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Cited by 94 Publications

Cell, 2019, 177(4):896-909

PubMed: 31030999 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4741

PubMed: 31628323 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1911393116

PubMed: 31732667 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Oncogene, 2019, 38(10):1639-1650

PubMed: 30337688 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

EBioMedicine, 2019, 40:151-162

PubMed: 30711516 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1693

PubMed: 30979895 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Cell Rep, 2019, 29(3):589-602

PubMed: 31618629 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0281-6

PubMed: 31467416 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):399

PubMed: 31113939 ( click the link to review the publication )

J Biol Chem, 2019, 294(10):3760-3771

PubMed: 30617181 ( click the link to review the publication )
Biochem Biophys Res Commun, 2019, 519(4):909-915

PubMed: 31563324 ( click the link to review the publication )

Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

Cell Metab, 2018, 28(3):369-382

PubMed: 30043754 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4831

PubMed: 30446646 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5426

PubMed: 30575721 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2819

PubMed: 30026551 ( click the link to review the publication )

J Pathol, 2018, 245(2):235-248

PubMed: 29570219 ( click the link to review the publication )

PLoS Genet, 2018, 14(5):e1007369

PubMed: 29750810 ( click the link to review the publication )

Development, 2018, 145(18)

PubMed: 30126904 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Braz J Med Biol Res, 2018, 51(6):e7080

PubMed: 29694502 ( click the link to review the publication )

Nat Commun, 2017, 8:15045

PubMed: 28429794 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Cell Res, 2017, 27(2):184-201

PubMed: 27934868 ( click the link to review the publication )

Mol Cell, 2017, 67(6):907-921

PubMed: 28844862 ( click the link to review the publication )

Mol Cell, 2017, 65(6):1029-1043

PubMed: 28306502 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Autophagy, 2017, 13(4):686-702

PubMed: 28121484 ( click the link to review the publication )

PLoS Pathog, 2017, 13(3):e1006249

PubMed: 28249048 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14544-14555

PubMed: 28684424 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(31):6625-6637

PubMed: 28697598 ( click the link to review the publication )
Radiat Res, 2017, 187(3):382-396

PubMed: 28327001 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93688-93703

PubMed: 29212182 ( click the link to review the publication )

Oncotarget, 2017, 8(52):89527-89538

PubMed: 29163768 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44550-44566

PubMed: 28562352 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(5):580-90

PubMed: 27025692 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

BMC Musculoskelet Disord, 2016, 17:150

PubMed: 27052304 ( click the link to review the publication )

Protein Cell, 2016, 7(12):878-887

PubMed: 27909983 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(5):1428-37

PubMed: 26938669 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(2):321-33

PubMed: 26582390 ( click the link to review the publication )

J Biol Chem, 2016, 291(33):17467-77

PubMed: 27339899 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55690-55703

PubMed: 27494886 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(8):e0135614

PubMed: 26267903 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:15

PubMed: 25849580 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1064-74

PubMed: 25283437 ( click the link to review the publication )
Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )

Sci Rep, 2015, 5:13891

PubMed: 26403635 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Cell Signal, 2015, 27(8):1557-68

PubMed: 25936523 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1214

PubMed: 24810050 ( click the link to review the publication )

J Biol Chem, 2014, 289(25):17830-42

PubMed: 24798333 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6816-31

PubMed: 25149175 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

Trends Microbiol, 2013, 21(6):286-95

PubMed: 23608036 ( click the link to review the publication )

Genes Dev, 2013, 27(10):1115-31

PubMed: 23699409 ( click the link to review the publication )

EMBO Mol Med, 2011, 3(4):189-200

PubMed: 21412983 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfvTWM2OD1yLkCwNFMxPiEQvF2=	Ml7RV2FPT0WU
OCUB-M	NFHGb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMECxPVQh\|ryP	NVyz[nAzW0GQR1XS
DOHH-2	NW\yWJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:3TWM2OD1yLkCwNlI2KM7:TR?=	NHvCc\|hUSU6JRWK=
NOS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3BXFZ1UUN3ME2wMlAxOjR{IN88US=>	MlG1V2FPT0WU
L-363	NF\ad3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMECyPFQh\|ryP	NGrvTYpUSU6JRWK=
RL95-2	NYfqelFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPsTWM2OD1yLkCwN\|Ih\|ryP	NX\odYxbW0GQR1XS
BL-70	NYTVeGN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfqN\|BvUUN3ME2wMlAxOzN5IN88US=>	Moj0V2FPT0WU
TGBC1TKB	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojuTWM2OD1yLkCwN\|c6KM7:TR?=	MWTTRW5ITVJ?
697	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEC2N\|Qh\|ryP	NEm1T\|dUSU6JRWK=
RPMI-8226	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrpc5poUUN3ME2wMlAxPjVzIN88US=>	MXnTRW5ITVJ?
BL-41	NF3HeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMEC2PVYh\|ryP	MYHTRW5ITVJ?
MRK-nu-1	M{H6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWeyU3lRUUN3ME2wMlAxPzB5IN88US=>	MX3TRW5ITVJ?
EW-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnZOZF7UUN3ME2wMlAxPzR7IN88US=>	Mm[0V2FPT0WU
EVSA-T	NXzMTnh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXRTWM2OD1yLkCwPFkzKM7:TR?=	Mny1V2FPT0WU
HUTU-80	NGDyWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMEC5Nlkh\|ryP	MmXRV2FPT0WU
VA-ES-BJ	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXMXHVCUUN3ME2wMlAxQTh2IN88US=>	MWDTRW5ITVJ?
GCIY	NVG3TI9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHy0eYtKSzVyPUCuNFExODdizszN	M{nGcnNCVkeHUh?=
ES6	NXvSWnRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXy3[HFOUUN3ME2wMlAyODh\|IN88US=>	NHHIR5JUSU6JRWK=
NALM-6	NIjtRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PyWWlEPTB;MD6wNVExOiEQvF2=	M{HpRnNCVkeHUh?=
LB996-RCC	M2mwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zHb2lEPTB;MD6wNVE{PyEQvF2=	MknJV2FPT0WU
EW-16	NIrhTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEGxPVIh\|ryP	MWTTRW5ITVJ?
KALS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTxTWM2OD1yLkCxNVk5KM7:TR?=	NVu4RlVyW0GQR1XS
OPM-2	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjsS5BKSzVyPUCuNFEzQSEQvF2=	MUDTRW5ITVJ?
KU812	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXqXplHUUN3ME2wMlAyOjl4IN88US=>	MYnTRW5ITVJ?
A4-Fuk	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PuUGlEPTB;MD6wNVMyQSEQvF2=	MlXJV2FPT0WU
KGN	NFjsTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXGXZRSUUN3ME2wMlAyOzV7IN88US=>	NX3kTVREW0GQR1XS
KS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXiTIVKSzVyPUCuNFE{QTJizszN	MXzTRW5ITVJ?
no-11	NFrxZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMEGzPVUh\|ryP	MUnTRW5ITVJ?
PSN1	NYH2WXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvmeWNKSzVyPUCuNFE1ODlizszN	MYXTRW5ITVJ?
SK-LMS-1	NIjDZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXoTWM2OD1yLkCxOFE{KM7:TR?=	MWLTRW5ITVJ?
LS-411N	NV\oRlBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEG0N\|kh\|ryP	Mn7mV2FPT0WU
HT-144	M{TXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml33TWM2OD1yLkCxOFUyKM7:TR?=	MnXvV2FPT0WU
ACN	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfHToNKSzVyPUCuNFE2KM7:TR?=	NWPUT4RyW0GQR1XS
RKO	NXnxUmZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NImyWItKSzVyPUCuNFE2OzNizszN	NYjUem5pW0GQR1XS
CMK	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjUWpRKSzVyPUCuNFE2PDNizszN	NEDsXVRUSU6JRWK=
GB-1	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXW2fpJoUUN3ME2wMlAyPTV\|IN88US=>	M{DhV3NCVkeHUh?=
KE-37	NH\sVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTBTWM2OD1yLkCxOVc{KM7:TR?=	NWHFVYpLW0GQR1XS
no-10	NWPyU4tZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfW[Jk1UUN3ME2wMlAyPTh2IN88US=>	NX\pPVA2W0GQR1XS
MOLT-16	NELnd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDWRZhKSzVyPUCuNFE3OjJizszN	MX;TRW5ITVJ?
HEL	NFPkWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj2TWM2OD1yLkCxOlQh\|ryP	NXm5VXM6W0GQR1XS
NCI-H1355	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLHb45KSzVyPUCuNFE3PDZizszN	Mly4V2FPT0WU
IST-MEL1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEG3O\|Qh\|ryP	M{nu[HNCVkeHUh?=
MHH-PREB-1	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEG4NVgh\|ryP	MU\TRW5ITVJ?
ES8	Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEG4OFQh\|ryP	NEH5NFhUSU6JRWK=
LC-2-ad	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDRTWM2OD1yLkCyNVM4KM7:TR?=	M3rLVHNCVkeHUh?=
LAMA-84	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUi0cGNtUUN3ME2wMlAzOTZ5IN88US=>	NXWxe3A6W0GQR1XS
BV-173	NYP6fWYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTifJFlUUN3ME2wMlAzOjB\|IN88US=>	M37xVHNCVkeHUh?=
SW872	NWThVIZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrKNlZKSzVyPUCuNFIzPDdizszN	M{LQVXNCVkeHUh?=
SK-UT-1	M1zaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7vTWM2OD1yLkCyNlYyKM7:TR?=	NX;mXndYW0GQR1XS
OS-RC-2	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEKzNlMh\|ryP	NEDUVm1USU6JRWK=
NCI-H747	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMEKzN{DPxE1?	NUjSTnh4W0GQR1XS
MZ2-MEL	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTXTWM2OD1yLkCyN\|M4KM7:TR?=	NVnUZWt2W0GQR1XS
TE-11	NF\GTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGC0enZKSzVyPUCuNFI{PzJizszN	NWfmT3VMW0GQR1XS
KURAMOCHI	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HqSWlEPTB;MD6wNlQyPCEQvF2=	M2TqfXNCVkeHUh?=
HD-MY-Z	NXHX[3p2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjiUZZ{UUN3ME2wMlAzPDJ4IN88US=>	NWHUZmQ{W0GQR1XS
GI-1	NEPse2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDZTZprUUN3ME2wMlAzPDZ7IN88US=>	M2DEV3NCVkeHUh?=
LB1047-RCC	MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HkdWlEPTB;MD6wNlQ5QCEQvF2=	MWTTRW5ITVJ?
TE-12	NWHPTYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMEK1OUDPxE1?	NF;PRlFUSU6JRWK=
MZ7-mel	NGPMcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfT[GJqUUN3ME2wMlAzPjB7IN88US=>	MknQV2FPT0WU
MMAC-SF	NIfzenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfoU4pKSzVyPUCuNFI3OzNizszN	MX\TRW5ITVJ?
A101D	NWrNepdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHzTWM2OD1yLkCyOlUh\|ryP	MkLaV2FPT0WU
GR-ST	NV3hWJF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVflUHVZUUN3ME2wMlAzPjV3IN88US=>	M3HFOnNCVkeHUh?=
MC116	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXnSmZKSzVyPUCuNFI3QCEQvF2=	NXH5O21zW0GQR1XS
Ramos-2G6-4C10	NUfIdpJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEK3OUDPxE1?	M4LnN3NCVkeHUh?=
ATN-1	MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTBTWM2OD1yLkCyO\|g6KM7:TR?=	MYjTRW5ITVJ?
MFH-ino	NFXHZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlf5TWM2OD1yLkCyPFEzKM7:TR?=	NXvFdHFmW0GQR1XS
DEL	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMEK4NVUh\|ryP	MoHEV2FPT0WU
OCI-AML2	NHzzdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPVWIpnUUN3ME2wMlAzQDdzIN88US=>	MnfPV2FPT0WU
LXF-289	NEfY[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PKOGlEPTB;MD6wNlg4OiEQvF2=	MlfxV2FPT0WU
IA-LM	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\ZepVKSzVyPUCuNFI6OTdizszN	NIDKenpUSU6JRWK=
EoL-1-cell	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nZdGlEPTB;MD6wNlk6PiEQvF2=	NVnKVJllW0GQR1XS
OVCAR-4	NHG3ZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTTfmpKSzVyPUCuNFMxQTRizszN	MYnTRW5ITVJ?
ES1	NUPaVXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXicYNKSzVyPUCuNFMxQTdizszN	M1e0PHNCVkeHUh?=
CESS	NYjjWmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHQfmhKSzVyPUCuNFMxQTlizszN	NYrEWmtKW0GQR1XS
GAK	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlS4TWM2OD1yLkCzNVg3KM7:TR?=	NYfjT4xFW0GQR1XS
NTERA-S-cl-D1	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nTO2lEPTB;MD6wN\|IzPiEQvF2=	M3zzVHNCVkeHUh?=
TE-10	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjv[WtKSzVyPUCuNFM{OTFizszN	NF62VIpUSU6JRWK=
CCRF-CEM	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEOzO\|Eh\|ryP	MmXMV2FPT0WU
NMC-G1	Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXJTWM2OD1yLkCzOFQ5KM7:TR?=	MV3TRW5ITVJ?
HOP-62	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFy2blRKSzVyPUCuNFM2PTZizszN	MlrtV2FPT0WU
SH-4	M2rQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHX0VXhKSzVyPUCuNFM2QDJizszN	NVrKNmlVW0GQR1XS
NCI-H1648	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLufW1WUUN3ME2wMlA{PjJ{IN88US=>	M2Hh[nNCVkeHUh?=
EB-3	M4X0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMEO2OFMh\|ryP	NVTPb3BvW0GQR1XS
BB65-RCC	NHTHOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;PToJKSzVyPUCuNFM3QTFizszN	NVXXPYxOW0GQR1XS
BE-13	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fGeWlEPTB;MD6wN\|c2QSEQvF2=	MXjTRW5ITVJ?
CP67-MEL	M4rn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jCO2lEPTB;MD6wN\|c2QSEQvF2=	MVfTRW5ITVJ?
SW954	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVWze4tQUUN3ME2wMlA{PzlizszN	NHq2OY1USU6JRWK=
TE-5	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XZWGlEPTB;MD6wN\|g2PCEQvF2=	Mly2V2FPT0WU
HCE-4	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMEO4OVUh\|ryP	MV3TRW5ITVJ?
LC-1F	M4HSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLyTWM2OD1yLkCzPVg6KM7:TR?=	NEfJcI9USU6JRWK=
TK10	M{HHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;abIZKSzVyPUCuNFQxOTlizszN	M1e1dXNCVkeHUh?=
SJSA-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHOSXNFUUN3ME2wMlA1OTh6IN88US=>	M4PVZ3NCVkeHUh?=
Daudi	NVTzWm13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnezTWM2OD1yLkC0NlI2KM7:TR?=	NH7nTVNUSU6JRWK=
SW982	M1rscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LzNWlEPTB;MD6wOFI1PiEQvF2=	NVnWPJBtW0GQR1XS
SF126	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDYTWM2OD1yLkC0N\|YyKM7:TR?=	MkDTV2FPT0WU
TE-15	M2jJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;kdYlDUUN3ME2wMlA1PDN3IN88US=>	MYrTRW5ITVJ?
COLO-684	Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3SxOmlEPTB;MD6wOFU3OSEQvF2=	M1vae3NCVkeHUh?=
8-MG-BA	NFToOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonRTWM2OD1yLkC0OlI6KM7:TR?=	M{DqRnNCVkeHUh?=
NB13	M1[1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfWbGVvUUN3ME2wMlA1Pzd4IN88US=>	NX3IephTW0GQR1XS
HCC1599	NIXyV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMES4O\|kh\|ryP	NXzTVpZ1W0GQR1XS
SK-PN-DW	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml:3TWM2OD1yLkC0PVQ6KM7:TR?=	M1;kZXNCVkeHUh?=
ALL-PO	NV3OSXBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMES5OVYh\|ryP	M1rMbXNCVkeHUh?=
NB6	NVrac5AzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33yb2lEPTB;MD6wOVI4OSEQvF2=	NF7xTFJUSU6JRWK=
IST-SL2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMEWzOlIh\|ryP	NXrh[ZAyW0GQR1XS
BB30-HNC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFWwblFKSzVyPUCuNFU4OyEQvF2=	NVPDN5NwW0GQR1XS
SW962	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEW3OlMh\|ryP	NEXVT3BUSU6JRWK=
TGBC24TKB	M2nqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMEW3PVkh\|ryP	NVfGVZk6W0GQR1XS
KINGS-1	M1jBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTPTWM2OD1yLkC1PFA{KM7:TR?=	NFPCfplUSU6JRWK=
HC-1	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjlNGNKSzVyPUCuNFU5OjdizszN	MUfTRW5ITVJ?
RS4-11	NIrUTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fPVmlEPTB;MD6wOVk{QCEQvF2=	M17aO3NCVkeHUh?=
LS-123	MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXDfpdqUUN3ME2wMlA2QTR{IN88US=>	NXPvVJVlW0GQR1XS
A3-KAW	MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvCTWM2OD1yLkC2NlI2KM7:TR?=	NXXlRXZYW0GQR1XS
SNB75	NYHJOpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwME[zOFEh\|ryP	MUHTRW5ITVJ?
SR	M{\GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3yybmlEPTB;MD6wOlM4PCEQvF2=	M4XTXnNCVkeHUh?=
LOUCY	M4\ueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlf5TWM2OD1yLkC2N\|k1KM7:TR?=	M4HzUnNCVkeHUh?=
K5	M{HxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XGUmlEPTB;MD6wOlQxOyEQvF2=	MWrTRW5ITVJ?
Becker	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLSTWM2OD1yLkC2OFIh\|ryP	MUPTRW5ITVJ?
CTV-1	NWnHTIFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jrU2lEPTB;MD6wOlU1QCEQvF2=	MULTRW5ITVJ?
KLE	M3O0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3q2eWlEPTB;MD6wOlU5PCEQvF2=	MYDTRW5ITVJ?
MZ1-PC	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLTTWM2OD1yLkC2OVk5KM7:TR?=	NWPHRVh3W0GQR1XS
MOLT-4	NH7zOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2iyfmlEPTB;MD6wOlYxPSEQvF2=	NILHRXVUSU6JRWK=
MLMA	M{DxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfLOGlKSzVyPUCuNFY4QCEQvF2=	MnL3V2FPT0WU
A388	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\UdWFKSzVyPUCuNFY5QTNizszN	MWTTRW5ITVJ?
MV-4-11	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e1R2lEPTB;MD6wOlk6PSEQvF2=	MlLEV2FPT0WU
DSH1	NYTWXmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHqeFJKSzVyPUCuNFcyPzNizszN	M2PkSXNCVkeHUh?=
MONO-MAC-6	M3XhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2i2R2lEPTB;MD6wO\|IyOiEQvF2=	M{\pSXNCVkeHUh?=
ARH-77	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{C5fGlEPTB;MD6wO\|I4QCEQvF2=	Mn7GV2FPT0WU
LB771-HNC	M2e4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\ib45KSzVyPUCuNFc2PDlizszN	M3jyV3NCVkeHUh?=
PF-382	M13WVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vmWGlEPTB;MD6wO\|U3QSEQvF2=	NVPlXmY1W0GQR1XS
KM12	NVjTeIZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;VTWM2OD1yLkC3OlQh\|ryP	MUPTRW5ITVJ?
HAL-01	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTYTWM2OD1yLkC3OlU5KM7:TR?=	NXrGT3JRW0GQR1XS
RPMI-8402	NV7aV4s3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\tXWlEPTB;MD6wO\|c5QSEQvF2=	M3\LT3NCVkeHUh?=
OMC-1	NWPWdHRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMEe4NFQh\|ryP	MUfTRW5ITVJ?
HT	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjmUHV{UUN3ME2wMlA5KM7:TR?=	NInBd\|dUSU6JRWK=
QIMR-WIL	NInLcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjVOW9KSzVyPUCuNFgxPTVizszN	NWDWeWxWW0GQR1XS
KNS-42	M4\4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEiyNFMh\|ryP	Ml;hV2FPT0WU
BC-3	NHXEflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2ToNWlEPTB;MD6wPFIxPCEQvF2=	M{TmO3NCVkeHUh?=
ES4	NHj4VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEiyPVYh\|ryP	MYLTRW5ITVJ?
NCI-H23	M1zxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELu[JNKSzVyPUCuNFg1PCEQvF2=	NWrZTJk6W0GQR1XS
LB2518-MEL	NXzmPJNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMEi2PVYh\|ryP	M3XMdnNCVkeHUh?=
LC4-1	NEfNe\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXzOGV1UUN3ME2wMlA5PzN6IN88US=>	NYqzdoZ{W0GQR1XS
SIG-M5	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFz5XIpKSzVyPUCuNFg6ODRizszN	MVjTRW5ITVJ?
LP-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvGOYp1UUN3ME2wMlA5QTN6IN88US=>	NUnofWtrW0GQR1XS
TE-8	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTQTWM2OD1yLkC5NFE3KM7:TR?=	MmLyV2FPT0WU
K-562	NVLkeVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHxdWhbUUN3ME2wMlA6OTJizszN	M3X3cHNCVkeHUh?=
J-RT3-T3-5	MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\wUFlLUUN3ME2wMlA6OTV\|IN88US=>	NEnYcY9USU6JRWK=
DU-4475	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\4TWM2OD1yLkC5NVY2KM7:TR?=	NXm5U2xOW0GQR1XS
RXF393	M2PySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMEm0OlIh\|ryP	NWXkVIJDW0GQR1XS
NB5	MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PiUWlEPTB;MD6wPVYzPSEQvF2=	NXLC[pI6W0GQR1XS
A704	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfoTWM2OD1yLkC5O\|QyKM7:TR?=	NHLLVHFUSU6JRWK=
SF268	NUGyZXVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEm4NlUh\|ryP	MXLTRW5ITVJ?
UACC-257	NG\1T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPwSo5WUUN3ME2wMlA6QDN\|IN88US=>	NFvHdnNUSU6JRWK=
L-428	M2nlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTtVIdDUUN3ME2wMlExOzJizszN	M1SyPXNCVkeHUh?=
ST486	M{TzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmX5TWM2OD1yLkGwOlA3KM7:TR?=	NXSzbWZrW0GQR1XS
SK-MM-2	M3rycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMUC3NFkh\|ryP	NWLkSoFrW0GQR1XS
COR-L279	M4nKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkD3TWM2OD1yLkGwPFMzKM7:TR?=	MVTTRW5ITVJ?
JiyoyeP-2003	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTVV4VKSzVyPUCuNVA5PDNizszN	MmDlV2FPT0WU
GT3TKB	MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMUC5NVgh\|ryP	NW\PO5FuW0GQR1XS
HCE-T	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXHd5B3UUN3ME2wMlExQTRizszN	NH\a[JlUSU6JRWK=
SBC-1	NYXG[ohZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fKSWlEPTB;MD6xNVEyQSEQvF2=	NU\qXmVbW0GQR1XS
KNS-81-FD	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jpRWlEPTB;MD6xNVI4OyEQvF2=	MmfXV2FPT0WU
NCI-H2126	M2[xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P3bGlEPTB;MD6xNVM6PCEQvF2=	MX3TRW5ITVJ?
EM-2	NUDwPZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMUG1Nlkh\|ryP	NYfRdZp{W0GQR1XS
JAR	NVvCWopKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jVTGlEPTB;MD6xNVU6QCEQvF2=	M{\WfHNCVkeHUh?=
NB17	M3yz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGT2ZpJKSzVyPUCuNVE3PTJizszN	NX7HfHNxW0GQR1XS
LB647-SCLC	M3faeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMUG3NFUh\|ryP	MmXGV2FPT0WU
CAL-148	NH;PNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMUG4JO69VQ>?	MWrTRW5ITVJ?
K052	NIrEcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXv4SpBjUUN3ME2wMlEyQDVzIN88US=>	NHzPSGxUSU6JRWK=
KARPAS-299	NF\XRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jqW2lEPTB;MD6xNlI{OyEQvF2=	NFjzSHZUSU6JRWK=
KARPAS-422	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMUK0N\|Ih\|ryP	MUXTRW5ITVJ?
LOXIMVI	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LQe2lEPTB;MD6xNlUyPSEQvF2=	MYnTRW5ITVJ?
SCC-3	NHy3fWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LiVWlEPTB;MD6xNlg2OSEQvF2=	MmjrV2FPT0WU
LU-139	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHnTWM2OD1yLkGyPVc2KM7:TR?=	MVvTRW5ITVJ?
COLO-320-HSR	NGmyeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrnU3oyUUN3ME2wMlE{ODh4IN88US=>	MXTTRW5ITVJ?
ONS-76	NYKyNHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTRTWM2OD1yLkGzNVMh\|ryP	MVjTRW5ITVJ?
U-266	M{HJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnsVlRKSzVyPUCuNVMzPDVizszN	MYnTRW5ITVJ?
HH	NF7E[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TNR2lEPTB;MD6xN\|U{PSEQvF2=	MmruV2FPT0WU
BB49-HNC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33jN2lEPTB;MD6xN\|U5PyEQvF2=	NFvEWYZUSU6JRWK=
NCI-SNU-5	NYPy[Y1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfCWoJKSzVyPUCuNVM2QTZizszN	NFz5PFdUSU6JRWK=
C2BBe1	NETPeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMUO3OFYh\|ryP	Mn\NV2FPT0WU
ML-2	NV:0NmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPUOZdKSzVyPUCuNVM6PTNizszN	NUm3[20xW0GQR1XS
SCH	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXCWHo3UUN3ME2wMlE{QTd2IN88US=>	MkXxV2FPT0WU
NCI-H82	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkT6TWM2OD1yLkG0NVA1KM7:TR?=	MlzwV2FPT0WU
MDA-MB-134-VI	NF35WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMUSyOVIh\|ryP	MULTRW5ITVJ?
SK-N-DZ	NYCzcIliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkThTWM2OD1yLkG0O\|E6KM7:TR?=	Mn\2V2FPT0WU
HL-60	NF3mVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPpfnNKSzVyPUCuNVQ6OiEQvF2=	NVPTfZlQW0GQR1XS
LB373-MEL-D	M3nTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDPR4NKSzVyPUCuNVU2OzlizszN	NWn3OFg1W0GQR1XS
LB831-BLC	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDO[HdKSzVyPUCuNVYxPzZizszN	NYDxWZF6W0GQR1XS
SK-NEP-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWizTXJWUUN3ME2wMlE3OTBzIN88US=>	MVHTRW5ITVJ?
IMR-5	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrZ[FNOUUN3ME2wMlE3PDh\|IN88US=>	NXzuelkxW0GQR1XS
Calu-6	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnENI4yUUN3ME2wMlE3PTN5IN88US=>	NX\CRoxqW0GQR1XS
NCI-H1882	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rlWGlEPTB;MD6xOlczQCEQvF2=	NUXudHZEW0GQR1XS
NCI-H446	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTWfnBKSzVyPUCuNVY5QTFizszN	MVHTRW5ITVJ?
GI-ME-N	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMUiwNkDPxE1?	MmHuV2FPT0WU
MPP-89	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnsPZNbUUN3ME2wMlE5OTJzIN88US=>	Moj5V2FPT0WU
CGTH-W-1	NU\F[FI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3Nc4FtUUN3ME2wMlE5PDN4IN88US=>	NEC5[ndUSU6JRWK=
MEG-01	NXL1c3I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMUi2Nlgh\|ryP	NWj0XHpQW0GQR1XS
NCI-H748	NUP4Uoh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvMTWM2OD1yLkG4PVEyKM7:TR?=	M2XRZXNCVkeHUh?=
COLO-829	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETse4FKSzVyPUCuNlA3PzNizszN	NHvzNndUSU6JRWK=
GOTO	M4j3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXSTolQUUN3ME2wMlIxPzNizszN	M4PIVnNCVkeHUh?=
EW-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPLVYdKSzVyPUCuNlE4OThizszN	MoTJV2FPT0WU
KY821	M2j6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7pZotKSzVyPUCuNlIxPDVizszN	NHj0b4FUSU6JRWK=
CTB-1	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HyV2lEPTB;MD6yNlIzQCEQvF2=	MkXsV2FPT0WU
TALL-1	NX63cldJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPhSYFKSzVyPUCuNlI6OjFizszN	MnvSV2FPT0WU
NCI-H209	NHjq[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\JTWM2OD1yLkKyPVYzKM7:TR?=	MnXvV2FPT0WU
IST-MES1	M2X0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7FfZlWUUN3ME2wMlI{PTFizszN	NHvhN4xUSU6JRWK=
DMS-114	NEflN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETLXGFKSzVyPUCuNlM6QTNizszN	Ml\3V2FPT0WU
SNU-C2B	M13iPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HvOGlEPTB;MD6yOFMyPiEQvF2=	MXjTRW5ITVJ?
DG-75	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUKwbIR4UUN3ME2wMlI3OTl3IN88US=>	NW\wenRRW0GQR1XS
D-336MG	NGLMOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDnZXFKSzVyPUCuNlY2PTdizszN	M1jucXNCVkeHUh?=
KMOE-2	MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\DWWlEPTB;MD6yO\|U{QCEQvF2=	NETTfZpUSU6JRWK=
NB1	NW\3cnZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DQRmlEPTB;MD6yO\|kzPiEQvF2=	NFq0fY1USU6JRWK=
RH-1	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmC2TWM2OD1yLkK3PVg6KM7:TR?=	MoHYV2FPT0WU
TE-1	M1\Gdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMki0O\|kh\|ryP	M1LTWnNCVkeHUh?=
RPMI-6666	NG\FTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMki4OEDPxE1?	MXjTRW5ITVJ?
TE-9	NVu2ZYttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHVb3h3UUN3ME2wMlI5QTh3IN88US=>	MXLTRW5ITVJ?
BT-474	NIC1R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfxbJBsUUN3ME2wMlI6OzN2IN88US=>	Mor1V2FPT0WU
COLO-668	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\y[2lEPTB;MD6yPVQzQSEQvF2=	NGe5VGpUSU6JRWK=
NCI-H1581	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3J[lZKSzVyPUCuNlk3QDlizszN	M3;ZNHNCVkeHUh?=
MN-60	M{DmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PyW2lEPTB;MD6yPVkxPSEQvF2=	NEPKdGVUSU6JRWK=
L-540	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TCNGlEPTB;MD6zNFA5OSEQvF2=	NV3pZYtzW0GQR1XS
MOLT-13	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XHPWlEPTB;MD6zNFE5OyEQvF2=	NEfBR2tUSU6JRWK=
NCI-SNU-16	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnKT3BnUUN3ME2wMlMxOjB3IN88US=>	M4jpUnNCVkeHUh?=
NCI-H64	M3jXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFT1bYRKSzVyPUCuN\|A{OzFizszN	MUXTRW5ITVJ?
CP66-MEL	NXfzPGEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvMdJlHUUN3ME2wMlMyPDF3IN88US=>	M1vOZ3NCVkeHUh?=
NB69	NH3ndHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwM{KxPFgh\|ryP	MWLTRW5ITVJ?
NCI-H2196	NYjIVFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3n5NGlEPTB;MD6zN\|A{PiEQvF2=	NYrNO2ppW0GQR1XS
MHH-CALL-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwM{O0Olgh\|ryP	NX3JVoxUW0GQR1XS
HCC2157	NWLmSWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInCO29KSzVyPUCuN\|M6PTRizszN	MYLTRW5ITVJ?
LS-1034	M1XtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoD4TWM2OD1yLkO2N\|g5KM7:TR?=	Mle2V2FPT0WU
BOKU	NFjWXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrXO2lxUUN3ME2wMlM4OTl7IN88US=>	NGfmWIFUSU6JRWK=
GDM-1	M2rKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwM{eyN\|Qh\|ryP	Mnv5V2FPT0WU
TGW	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPUclc2UUN3ME2wMlM4PDV\|IN88US=>	NUXrXYk3W0GQR1XS
SNU-C1	NFvFW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4T2eGlEPTB;MD6zPFIyPSEQvF2=	NFrJbnZUSU6JRWK=
LS-513	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwM{mwO\|Eh\|ryP	NXLxXHB1W0GQR1XS
NOMO-1	NFjCbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nm[2lEPTB;MD6zPVk4OSEQvF2=	MlHNV2FPT0WU
MS-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljOTWM2OD1yLkSwNVc4KM7:TR?=	MoTHV2FPT0WU
EKVX	NEDu[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTrTWM2OD1yLkS0OFYyKM7:TR?=	M1y0WXNCVkeHUh?=
SK-MEL-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUj0eJpFUUN3ME2wMlQ3PCEQvF2=	M1PEd3NCVkeHUh?=
HCC1187	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:5d3BKSzVyPUCuOFY4PjhizszN	MmnDV2FPT0WU
HCC2218	NGL4fHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7uTWM2OD1yLkS3NlI4KM7:TR?=	NYPJTXZXW0GQR1XS
NCI-H187	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37BSmlEPTB;MD60O\|g1KM7:TR?=	M4rlVHNCVkeHUh?=
DB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwNUCwOVUh\|ryP	NV\kZXpZW0GQR1XS
NCI-H69	MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HKd2lEPTB;MD61NFI1PyEQvF2=	MU\TRW5ITVJ?
NCI-H1694	NVfwSHJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml[zTWM2OD1yLkWwOlk4KM7:TR?=	NVnHNlFKW0GQR1XS
CA46	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHFTWM2OD1yLkWwPVE4KM7:TR?=	MlTyV2FPT0WU
EHEB	M1:0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGmzZ3BKSzVyPUCuOVEyQTNizszN	MX3TRW5ITVJ?
NCCIT	NWW3NGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwNUSzNlEh\|ryP	MnnYV2FPT0WU
NCI-H720	NEjic21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O2NGlEPTB;MD61OFk3OiEQvF2=	Mlv6V2FPT0WU
LU-134-A	M1\0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTWW5pbUUN3ME2wMlU2Ojl4IN88US=>	MYLTRW5ITVJ?
MC-CAR	NUO5[JBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLlTWM2OD1yLkW1OFMyKM7:TR?=	M{G3PXNCVkeHUh?=
NEC8	M1LxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXkR2lUUUN3ME2wMlU3OTd{IN88US=>	M2PINHNCVkeHUh?=
NCI-H524	NV3PO4xKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnoPYdKSzVyPUCuOVg4PDhizszN	MXTTRW5ITVJ?
NCI-H1963	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LadWlEPTB;MD62NlU5KM7:TR?=	M1\MVHNCVkeHUh?=
SU-DHL-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELOUY5KSzVyPUCuOlQ2OjZizszN	MnLQV2FPT0WU
NCI-H1522	MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjPb41JUUN3ME2wMlY1QDh\|IN88US=>	NXfuSm4zW0GQR1XS
NCI-H1155	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXPTWM2OD1yLk[1N\|Uh\|ryP	NWjaN\|Z5W0GQR1XS
D-263MG	NF:3dVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrzfZBKSzVyPUCuOlYyODFizszN	M2rrUXNCVkeHUh?=
TE-6	M3LHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXHTWM2OD1yLk[4NVA1KM7:TR?=	M3PkSnNCVkeHUh?=
NCI-H1417	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwNkm3NVEh\|ryP	NXf2PYdPW0GQR1XS
NCI-H510A	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HGV2lEPTB;MD63O\|I{PiEQvF2=	NUnHOXltW0GQR1XS
KARPAS-45	NH7WWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGX3W5pKSzVyPUCuO\|gzOzVizszN	M{HDenNCVkeHUh?=
IST-SL1	MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLpTWM2OD1yLki1PFI2KM7:TR?=	NXjxbYx1W0GQR1XS
COLO-824	M37DTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vrOWlEPTB;MD64O\|g{PSEQvF2=	M3H6fXNCVkeHUh?=
NCI-H526	NIHCXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjTOWlbUUN3ME2wMlkxQTV6IN88US=>	MVHTRW5ITVJ?
NCI-H719	M3jTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwOU[2OVch\|ryP	MlPSV2FPT0WU
SF539	NIrBRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrvb5NuUUN3ME2wMlk5Ozl4IN88US=>	MXLTRW5ITVJ?
NKM-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3zbYhJUUN3ME2wMlk5PjZ\|IN88US=>	NHqzOYRUSU6JRWK=
A253	NHe3XFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjYTWM2OD1yLkm4PFg2KM7:TR?=	NFvrWZZUSU6JRWK=
TE-441-T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPMXFlKSzVyPUGuNFQ{PSEQvF2=	M1zF[nNCVkeHUh?=
COR-L88	NF3kXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPWTWM2OD1zLkGxN\|U1KM7:TR?=	NXfUe3BUW0GQR1XS
CPC-N	NFfUNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfVR3k6UUN3ME2xMlE2QDh6IN88US=>	NXnGdI9GW0GQR1XS
NCI-H2107	NVPhO\|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nhSWlEPTB;MT6xO\|I3OSEQvF2=	MY\TRW5ITVJ?
ECC4	M1e1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTFwMUi2PVMh\|ryP	MXvTRW5ITVJ?
NCI-H2141	NVS2R\|l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\Q[pFKSzVyPUGuNVkzQTlizszN	M3nac3NCVkeHUh?=
NCI-H1770	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\UXYJKSzVyPUGuN\|I6OjhizszN	NWHkSXNJW0GQR1XS
NCI-SNU-1	NGDveZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TxV2lEPTB;MT6zN\|A1KM7:TR?=	NXz6NVU2W0GQR1XS
LU-165	M3L6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTFwNEW0Olch\|ryP	NWq0N29kW0GQR1XS
Raji	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;lTWM2OD1zLkS3NlU6KM7:TR?=	NY\ZXHlkW0GQR1XS
EW-24	NYXxPZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HJS2lEPTB;MT61OFYyQSEQvF2=	NVuwWJVDW0GQR1XS
KP-N-RT-BM-1	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXSd5dYUUN3ME2xMlU3PTVzIN88US=>	MX7TRW5ITVJ?
SK-MEL-1	M4PUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\OTWM2OD1zLk[0PFc4KM7:TR?=	MVTTRW5ITVJ?
SCLC-21H	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2n1XGlEPTB;MT62OlY2OSEQvF2=	MXfTRW5ITVJ?
SIMA	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXzdoczUUN3ME2xMlY5OjN\|IN88US=>	NIm1cWNUSU6JRWK=
NCI-H1304	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXTc5hzUUN3ME2xMlcxPzZ3IN88US=>	NXi2Xo9uW0GQR1XS
REH	NEnMPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFwN{GwO\|gh\|ryP	NHr5[mxUSU6JRWK=
KP-N-YS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofETWM2OD1zLkmzOVUyKM7:TR?=	NWrVOlNEW0GQR1XS
DMS-153	M4LIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEf1UmdKSzVyPUGuPVc2QSEQvF2=	MYnTRW5ITVJ?
NB10	NUHBW\|RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7UcWxKSzVyPUKuNlA5PzhizszN	M{X6NnNCVkeHUh?=
NCI-H345	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrUTWM2OD1{Lk[xPVA2KM7:TR?=	NIm0bVlUSU6JRWK=
SK-N-FI	M4rXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTJwN{WzPFEh\|ryP	NVzxW2NzW0GQR1XS
NCI-H1092	M2nHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vuW2lEPTB;Mj65OVM6PCEQvF2=	Mlr0V2FPT0WU
KM-H2	NXvXbHhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrRZoRHUUN3ME2zMlY2Ozl4IN88US=>	MkTuV2FPT0WU
KG-1	NX61OG9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfJe4xwUUN3ME2zMlcyPjh6IN88US=>	NYjRWW43W0GQR1XS
D-283MED	M4Wx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPWfpZkUUN3ME2zMlc2QDdizszN	NFPUU2tUSU6JRWK=
LU-65	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDYOXBKSzVyPUSuNVE1QDVizszN	NXntPZBPW0GQR1XS
MSTO-211H	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTxUXQ5UUN3ME20MlE5QDl6IN88US=>	NWrneYJZW0GQR1XS
NCI-H2081	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTRwMkmxO\|Qh\|ryP	MULTRW5ITVJ?
D-247MG	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX1RpRKSzVyPUSuOFMyQTFizszN	NWG5O3djW0GQR1XS
P31-FUJ	M1LKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jHemlEPTB;ND60OVAyQSEQvF2=	NFfDS4xUSU6JRWK=
DMS-79	M4SyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF62fJFKSzVyPUSuPVMyQDNizszN	M1XzeXNCVkeHUh?=
KASUMI-1	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3TR3FKSzVyPUSuPVc2ODlizszN	NWCxXFZpW0GQR1XS
JVM-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jyeGlEPTB;NT6yOVAyPCEQvF2=	MXPTRW5ITVJ?
LAN-6	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHvTWM2OD13LkWxO\|M3KM7:TR?=	NHrkdXhUSU6JRWK=
DJM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkK3TWM2OD13LkW2NFI6KM7:TR?=	NFnLTodUSU6JRWK=
JVM-2	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnyblZKSzVyPUWuOlcxQTJizszN	NYTLXJBqW0GQR1XS
U-87-MG	NYfac3F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHDTWM2OD13Lki5PVY1KM7:TR?=	NI\ZO3hUSU6JRWK=
SHP-77	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTVwOUS5Nlgh\|ryP	NXjRNZhIW0GQR1XS
RPMI-8866	NVLFOJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnOdoFNUUN3ME22MlI4ODF\|IN88US=>	NVnKbZJVW0GQR1XS
ES7	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PnR2lEPTB;Nj6zPVkzPCEQvF2=	NYDEVlh6W0GQR1XS
WSU-NHL	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\rWlA6UUN3ME22MlUyPjB7IN88US=>	NFrscFlUSU6JRWK=
CAS-1	NHraS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrLXYNKSzVyPUeuNFk4PDlizszN	MV3TRW5ITVJ?
MHH-NB-11	NWLJeo9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRThwMkOxOVIh\|ryP	NHuzeXRUSU6JRWK=
ES5	NIXydZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTlwNUKyPFYh\|ryP	MWHTRW5ITVJ?
HDLM-2	NH:2[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTlwOUW5NFIh\|ryP	NVrhPVl5W0GQR1XS
NCI-H2171	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7vTWM2OD1zMD61PVI4KM7:TR?=	M16wSnNCVkeHUh?=
LNCaP-Clone-FGC	M2Tsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFzLkO3NVgh\|ryP	MnzYV2FPT0WU
NCI-H1395	NVG5NmxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLYTWM2OD1zMj6yOlk6KM7:TR?=	M3q3PXNCVkeHUh?=
NCI-H1436	M13xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTF\|LkOxPVUh\|ryP	NXv3TYdUW0GQR1XS
RCC10RGB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvFTWM2OD1zMz6zNlIyKM7:TR?=	MVzTRW5ITVJ?
SW684	NVXlcGd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\4XmRKSzVyPUGzMlk4QTdizszN	MmPsV2FPT0WU
NCI-H1650	NV;RUHFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTF3LkC0OFch\|ryP	MXnTRW5ITVJ?
EW-13	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkf5TWM2OD1zNT6yNFIyKM7:TR?=	M4PaN3NCVkeHUh?=
EC-GI-10	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTF3Lki2OFQh\|ryP	NUnB[WRYW0GQR1XS
CHP-126	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTF5LkG5NVgh\|ryP	MYLTRW5ITVJ?
NCI-H226	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;iRYxKSzVyPUG4MlA1ODNizszN	NWnhWlNCW0GQR1XS
NCI-H1838	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJyLkG4OFgh\|ryP	MkjxV2FPT0WU
EW-11	MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTJ2LkK3NVgh\|ryP	NILlUI5USU6JRWK=
EB2	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTNzLkWzNVgh\|ryP	NVHlOoI{W0GQR1XS
D-502MG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTR\|LkmyNlkh\|ryP	M{nrdXNCVkeHUh?=
U-698-M	NXTHOIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe5[JVNUUN3ME20PE45PjdzIN88US=>	MYDTRW5ITVJ?
ES3	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGmydJZKSzVyPUS5MlM5QTNizszN	MmHJV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	- Collapse Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

- Collapse

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1

Cited by 94 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Torin 1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1

Cited by 94 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Torin 1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)